An update on clinical outcomes in heart and lung transplantation

Transplantation

Volumn 77, Issue 9, 2004, Pages

  Garrity Jr , Edward R ^a   Mehra, Mandeep R ^b  

^a LOYOLA UNIVERSITY CHICAGO   (United States)

^b OCHSNER CLINIC FOUNDATION   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AZATHIOPRINE; CALCINEURIN INHIBITOR; CORTICOSTEROID; CYCLOSPORIN; IMMUNOSUPPRESSIVE AGENT; METHOTREXATE; METHYLPREDNISOLONE; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER; OKT 3; RAPAMYCIN; STEROID; TACROLIMUS; THYMOCYTE ANTIBODY;

CYTOMEGALOVIRUS INFECTION; DRUG EFFICACY; DRUG SAFETY; GINGIVA HYPERPLASIA; GRAFT FAILURE; GRAFT REJECTION; HEART LUNG TRANSPLANTATION; HIRSUTISM; HUMAN; HYPERLIPIDEMIA; HYPERTENSION; IMMUNOSUPPRESSIVE TREATMENT; KIDNEY DYSFUNCTION; PRIORITY JOURNAL; REVIEW; SURVIVAL RATE;

EID: 2442640140     PISSN: 00411337     EISSN: None     Source Type: Journal    
DOI: 10.1097/01.tp.0000126930.57516.28     Document Type: Review

References (45)

1. Hertz MI, Mohaesi PJ, Taylor DO, et al. The registry of the International Society for Heart and Lung Transplantation: introduction for the twentieth annual report: 2003. J Heart Lung Transplant 2003; 22(6): 610.
2. Rodeheffer RJ, McGregor CG. The development of cardiac transplantation. Mayo Clin Proc 1992; 67: 480.
3. Hardy JD, Chavez CM, Kurrus FD, et al. Heart transplantation in man: developmental studies and report of a case. JAMA 1964; 118: 114.
4. Barnard CN. A human cardiac transplant: an interim report of a successful operation performed at Groote Schuur Hospital, Cape Town. S Afr Med J 1967; 41: 1271.
5. Trulock EP, Edwards LB, Taylor DO, et al. The Registry of the International Society for Heart and Lung Transplantation: Twentieth official adult lung and heart-lung transplant report: 2003. J Heart Lung Transplant 2003; 22(6): 625.
6. Hosenpud JD, Bennett LE, Keck BM, et al. The Registry of the International Society for Heart and Lung Transplantation: Fourteenth official report: 1997. J Heart Lung Transplant 1997; 16(7): 691.
7. Mehra MR, Ventura HO, Chambers RB, et al. The prognostic impact of immunosuppression and cellular rejection on cardiac allograft vasculopathy: time for a reappraisal. J Heart Lung Transplant 1997; 16: 743.
8. Chan MC, Kwok BW, Shiba N, et al. Conversion of cyclosporine to tacrolimus for refractory or persistent myocardial rejection. Transplant Proc 2002; 34: 1850.
9. Meiser BM, Uberfuhr P, Fuchs A, et al. Tacrolimus: a superior agent to OKT3 for treating cases of persistent rejection after intrathoracic transplantation. J Heart Lung Transplant 1997; 16: 795.
10. Kobashigawa JA, Kasiske B. Hyperlipidemia in solid organ transplantation. Transplantation 1997; 63: 331.
11. Taylor DO, Barr ML, Radovancevic B, et al. A randomized, multicenter comparison of tacrolimus and cyclosporine immunosuppressive regimens in cardiac transplantation: decreased hyperlipidemia and hypertension with tacrolimus. J Heart Lung Transplant 1999; 18(4): 336.
12. Reichart B, Meiser B, Vigano M, et al. European multicenter tacrolimus (FK506) heart pilot study: one-year results. European Tacrolimus Multicenter Heart Group. J Heart Lung Transplant 1998; 17: 775.
13. Grimm M, Rinaldi M, Yonan NA, for the European Tacrolimus Heart Study Group. Efficacy and safety of tacrolimus (TAC) vs cyclosporine microemulsion (CME) in de novo cardiac transplant recipients: 6-month results [Abstract]. J Heart Lung Transplant 2003; S92.
14. Osanger DR, Canver CC, Jahania, MS, et al. Efficacy of tacrolimus in the treatment of refractory rejection in heart and lung transplant recipients. J Heart Lung Transplant 1999; 18: 448.
15. Mentzer Jr RM, Jahania MS, Lasley RD, and the US Multicenter FK506 Study Group. Tacrolimus as a rescue immunosuppressant after heart and lung transplantation. Transplantation 1998; 65: 109.
16. De Bonis M, Reynolds L, Barros J, et al. Tacrolimus as a rescue immunosuppressant after heart transplantation. Eur J Cardiothorac Surg 2001; 19: 690.
17. Mehra MR, Uber PA, Park MH, et al. A randomized comparison of an immunosuppressive strategy using tacrolimus and cyclosporine in black heart transplant recipients. Transplant Proc 2001; 33: 1606.
18. Mehra MR, Uber PA, Scott RL, et al. Ethnic disparity in clinical outcome after heart transplantation is abrogated using tacrolimus and mycophenolate mofetil-based immunosuppression. Transplantation 2002; 74: 1568.
19. Teebken OE, Strüber M, Harringer W, et al. Primary immunosuppression with tacrolimus and mycophenolate mofetil versus cyclosporine and azathioprine in heart transplant recipients. Transplant Proc 2002; 34: 1265.
20. Pham SM, Qi XS, Mallon SM, et al. Sirolimus and tacrolimus in clinical cardiac transplantation. Transplant Proc 2002; 1839.
21. Hardy JD. Lung homotransplantations in man: report of the initial ease. JAMA 1963; 186: 99.
22. Derom F, Barbier F, Ringoir S, et al. Ten month survival after lung homotransplantation in man. J Thorac Cardiovasc Surg 1997; 61: 835.
23. Reitz BA, Wallwork JL, Hunt SA, et al. Heart-lung transplantation: successful therapy for patients with pulmonary vascular disease. N Engl J Med 1982; 306: 557.
24. Bando K, Paradis IL, Similo S, et al. Obliterative bronchiolitis after lung and heart-lung transplantation: an analysis of risk factors and management. J Thorac Cardiovasc Surg 1995; 110: 4.
25. Heng D, Sharples LD, McNeil K, et al. Bronchiolitis obliterans syndrome: incidence, natural history, prognosis, and risk factors. J Heart Lung Transplant 1998; 17: 1255.
26. Revell MP, Lewis ME, Llewellyn-Jones CG, et al. Conservation of small-airway function by tacrolimus/cyclosporine conversion in the management of bronchiolitis obliterans following lung transplantation. J Heart Lung Transplant 2000; 19: 1219.
27. United Network for Organ Sharing (UNOS). U.S. lung transplants performed between 1988 and 2003. Available at: www.optn.org/latestData/rptData.asp. Accessed January 12, 2004.
28. Lipson DA, Palevsky HI, Kotloff RM, et al. Conversion to tacrolimus (FK506) from cyclosporine after orthotopic lung transplantation. Transplant Proc 1998; 30: 1505.
29. Garrity ER Jr, Hertz MI, Trulock EP, et al. Suggested guidelines for the use of tacrolimus in lung-transplant recipients [Editorial]. J Heart Lung Transplant 1999; 175.
30. Kennan RJ, Konishi H, Kawai A, et al. Clinical trial of tacrolimus versus cyclosporine in lung transplantation. Ann Thorac Surg 1995; 60: 580.
31. Vitulo P, Oggionni T, Cascina A, et al. Efficacy of tacrolimus rescue therapy in refractory acute rejection after lung transplantation. J Heart Lung Transplant 2002; 21: 435.
32. Horning NR, Lynch JP, Sundaresan SR, et al. Tacrolimus therapy for persistent or recurrent acute rejection after lung transplantation, J Heart Lung Transplant 1998; 17: 761.
33. Sarahrudi K, Carretta A, Wisser W, et al. The value of switching from cyclosporine to tacrolimus in the treatment of refractory acute rejection and obliterative bronchiolitis after lung transplantation. Transpl Int 2002; 15: 24.
34. Cairn J, Yek T, Banner NR, et al. Time-related changes in pulmonary function after conversion to tacrolimus in bronchiolitis obliterans syndrome. J Heart Lung Transplant 2003; 22: 50.
35. Verleden GM, Dupont LJ, Van Raemdonck D, et al. Effect of switching from cyclosporine to tacrolimus on exhaled nitric oxide and pulmonary function in patients with chronic rejection after lung transplantation. J Heart Lung Transplant 2003; 22: 908.
36. Treede H, Klepetko W, Reichenspurner H, et al. Tacrolimus versus cyclosporine after lung transplantation: a prospective, open, randomized two-center trial comparing two different immunosuppressive protocols. J Heart Lung Transplant 2001; 20: 511.
37. Kur F, Reichenspurner H, Meiser BM, et al. Tacrolimus (FK506) as primary immunosuppressant after lung transplantation. Thorac Cardiovasc Surg 1999; 47: 174.
38. Izbicki G, Shitrit D, Aravot D, et al. Improved survival after lung transplantation in patients treated with tacrolimus/mycophenolate mofetil as compared with cyclosporine/azathioprine. Transplant Proc 2002; 34: 3258.
39. Bhorade SM, Jordan A, Villaneuva J, et al. Comparison of three tacrolimus-based immunosuppressive regimens in lung transplantation. Am J Transplant 2003; 3: 1570.
40. Reichenspurner H, Kur F, Treede H, et al. Optimization of the immunosuppressive protocol after lung transplantation. Transplantation 1999; 68: 67.
41. Bostom AD, Brown RS Jr, Chavers BM, et al. Prevention of post-transplant cardiovascular disease: report and recommendations of an ad hoc group. Am J Transplant 2002; 2: 491.
42. White M, for the Canadian Heart Transplant Group. Prograf decreases plasma cholesterol in heart transplant recipients with treated but persisting mild dyslipidemia: the Canadian multicenter randomized trial of Prograf versus Neoral [Abstract]. J Heart Lung Transplant 2003; 205: S140.
43. Ishani A, Erturk S, Hertz MI, et al. Predictors of renal function following lung or heart-lung transplantation. Kid Int 2002; 61: 2228.
44. Israni A, Brozena S, Pankewycz O, et al. Conversion to tacrolimus for the treatment of cyclosporine-associated nephrotoxicity in heart transplant recipients. Am J Kid Dis 2002; 39: 1.
45. Taylor DO, Barr ML, Meiser BM, et al. Suggested guidelines for the use of tacrolimus in cardiac transplant recipients. J Heart Lung Transplant 2001; 20: 734.